Woundchek Protease Status is designed to assess protease activity in non-healing chronic wounds.

Systagenix Global Marketing vice president Paolo Di Vincenzo said Woundchek Protease Status helps clinicians establish within minutes which wounds may most benefit from a protease modulating therapy, ensuring appropriate and targeted use of these therapies.

Systagenix CEO Ernest Waaser said this collaboration with Alere provides it with access to unmatched point of care diagnostic test development expertise, an already proven point of care diagnostic technology platform and regulatory and manufacturing capabilities that considerably accelerate commercialization.